切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (02) : 217 -222. doi: 10.3877/cma.j.issn.1674-1358.2016.02.018

临床论著

综合治疗策略对我国丙型肝炎相关性肝癌患者的预后因素分析
常中飞1, 郑玉琴1, 刘凤永2, 段峰2, 王志军2, 王茂强2,()   
  1. 1. 100043 北京,首都医科大学石景山教学医院北京市石景山医院中医科
    2. 100853 北京,解放军总医院介入放射科
  • 收稿日期:2015-05-13 出版日期:2016-04-15
  • 通信作者: 王茂强

Efficacy and prognostic factors of transarterial chemoembolization combined with multimodality treatments strategies for hepatitis C virus-related hepatocellular carcinoma in China

Zhongfei Chang1, Yuqin Zheng1, Fengyong Liu2, Feng Duan2, Zhijun Wang2, Maoqiang Wang2,()   

  1. 1. Department of Traditional Chinese Medicine, Beijing Shijianshan Hospital, Shijingshan Teaching Hospital of Capital Medical University, Beijing 100043, China
    2. Department of Interventional Radiology, PLA General Hospital, Beijing 100853, China
  • Received:2015-05-13 Published:2016-04-15
  • Corresponding author: Maoqiang Wang
引用本文:

常中飞, 郑玉琴, 刘凤永, 段峰, 王志军, 王茂强. 综合治疗策略对我国丙型肝炎相关性肝癌患者的预后因素分析[J/OL]. 中华实验和临床感染病杂志(电子版), 2016, 10(02): 217-222.

Zhongfei Chang, Yuqin Zheng, Fengyong Liu, Feng Duan, Zhijun Wang, Maoqiang Wang. Efficacy and prognostic factors of transarterial chemoembolization combined with multimodality treatments strategies for hepatitis C virus-related hepatocellular carcinoma in China[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(02): 217-222.

目的

评价单纯应用经导管动脉内化疗(TACE)及综合治疗丙型肝炎相关性肝细胞癌(HCV-HCC)的临床疗效、生存状况及预后分析。

方法

回顾性分析2008年8月至2011年12月解放军总医院介入放射科收治的139例丙型肝炎相关性肝癌患者,按照治疗方式不同,分为单纯TACE治疗组96例(TACE组)和TACE-联合治疗组43例,分析其生存情况及预后因素。

结果

TACE组患者的1、2和3年生存率分别为79.2%、43.8%和24.0%;综合治疗组患者的1、2和3年生存率分别为86.0%、76.7%和58.1%。TACE组与综合治疗组在生存率方面,差异具有统计学意义(χ2 = 8.691,P = 0.003)。单因素分析结果显示,Child分级、有无门脉癌栓、甲胎蛋白(AFP)、肿瘤大小、肿瘤数目、美国东部肿瘤协作组(ECOG)评分、治疗方式及巴塞罗那临床肝癌(BCLC)分期均为影响丙型肝炎相关性肝癌患者长期生存的危险因素。Cox回归分析结果显示,肿瘤大小、治疗方式、BCLC分期、有无门脉癌栓和AFP水平是丙型肝炎相关性HCC患者预后的独立危险因素,差异均具有统计学意义(P均< 0.05)。

结论

综合治疗丙型肝炎相关性肝癌是延长患者生存期有效的治疗方法。

Objective

To evaluate the efficacy, survival and prognosis of transarterial chemoembolization (TACE) alone and TACE in combination with multimodality therapy for the hepatitis C virus-related hepatocellular carcinoma (HCV-HCC).

Methods

The clinical data of 139 patients with HCV-HCC treated in PLA General Hospital from August 2008 to December 2011 were analyzed, retrospectively. Among them, 96 patients were treated with TACE alone (TACE group) and 43 patients treated with TACE plus multimodality therapy (TACE-combined treatment group), according to the different treatment modalities. All the clinicopathological and survival data were analyzed.

Results

The median follow-up of the 139 cases was 23 months (range 1-40 months). The 1-, 2-, and 3-year overall survival (OS) rates of the TACE group were 79.2%, 43.8% and 24.0%, respectively; while 86.0%, 76.7% and 58.1%, respectively, for the combined treatment group (χ2 = 8.691, P = 0.003). The univariate analysis showed that the patients’ gender, age and cirrhosis were not significantly correlated with prognosis of the patients (P all > 0.05), but multimodality therapy, Child’s grading, ECOG scores, levels of AFP, tumor sizes, tumor numbers, portal vein tumor thrombus and BCLC grade were significantly related to overall survival. Moreover, the Cox multivariant survival analysis revealed that tumor size, portal vein tumor thrombus, levels of AFP and BCLC grade were independent prognostic indicators to HCV-HCC, with significant differences (P all < 0.05).

Conclusions

Multimodality therapy is a safe and effective treatment method for hepatitis C virus-related hepatocellular carcinoma.

表1 TACE组和综合治疗组患者的临床特征[例(%)]
临床特征 病例总数(n =139) TACE组(n = 96) 综合治疗组(n = 43) χ2 P
性别       1.035 0.309
  109(78.42) 73(76.04) 36(83.72)    
  30(21.58) 23(23.96) 7(16.28)    
年龄(岁)       1.031 0.310
  ≥ 60 102(73.38) 68(70.83) 34(79.07)    
  < 60 37(26.62) 28(29.17) 9(20.93)    
Child分级       3.294 0.070
  A 106(76.26) 69(71.87) 37(86.05)    
  B 33(23.74) 27(28.13) 6(13.95)    
肝硬化       0.647 0.421
  124(89.21) 87(90.63) 37(86.05)    
  15(10.79) 9(9.37) 6(13.95)    
ECOG评分       1.113 0.287
  0~1分 99(71.22) 71(73.96) 28(65.12)    
  2分 40(28.78) 25(26.04) 15(34.88)    
肿瘤数目       2.401 0.121
  单发 87(62.59) 56(58.33) 31(72.09)    
  多发 52(37.41) 40(41.67) 12(27.91)    
肿瘤大小(cm)       0.689 0.406
  ≥ 5 91(65.47) 65(67.71) 26(60.47)    
  < 5 48(34.53) 31(32.29) 17(39.53)    
AFP水平(µg/L)       0.130 0.718
  > 400 45(32.37) 32(33.33) 13(30.23)    
  ≤ 400 94(67.63) 64(66.67) 30(69.77)    
门静脉癌栓       0.021 0.885
  17(12.23) 12(12.50) 5(11.63)    
  122(87.77) 84(87.50) 38(88.37)    
BCLC分期       0.172 0.678
  B期 122(87.77) 85(88.54) 37(86.05)    
  C期 17(12.23) 11(11.46) 6(13.95)    
图1 不同治疗方式对生存率的影响
表2 139例丙型肝炎相关HCC患者预后影响因素的单因素分析
表3 丙型肝炎相关性HCC患者预后影响因素的Cox模型多因素分析
[1]
El-Serag HB. Hepatocellular carcinoma[J]. N Engl J Med,2011,365(12):1118-1127.
[2]
E1-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. GastroenteroIogy,2012,142(6):1264-1273.
[3]
成军. 慢性丙型肝炎治疗的过去,现在和未来[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(1):4-5.
[4]
中华人民共和国卫生部(卫办医政发[2011]12l号). 原发性肝癌诊疗规范(2011年版)[J]. 中华肝脏病杂志,2012,20(6):419-426.
[5]
中华医学会传染病与寄生虫病学分会,中华医学会肝病学分会. 病毒性肝炎防治方案[J]. 中华传染病杂志,2001,19(1):56-62.
[6]
庄辉. 加强对新生儿以外人群乙型肝炎疫苗免疫[J]. 中华流行病学杂志,2004,25(5):376-377.
[7]
陈园生,王旭霞,尚鹏辉, 等. 中国人群乙型肝炎病毒表面抗原流行规律变迁的初步研究[J/CD]. 中华实验和临床感染病杂志:电子版,2007,1(1):20-21.
[8]
常中飞,陈文彰,孙红梅, 等. 吸烟对经导管动脉内化疗治疗中期男性原发性肝癌患者预后的影响[J/CD]. 中华临床医师杂志:电子版,2015,9(7):1125-1128.
[9]
常中飞,陈文彰,孙红梅. 等. 肝动脉灌注化疗治疗丙型肝炎相关性肝癌临床疗效及预后因素分析[J/CD]. 中华临床医师杂志:电子版,2015,9(8):1322-1325.
[10]
康海燕,常中飞,刘凤永, 等. 经导管动脉内化疗治疗高龄原发性肝癌患者生存分析[J]. 中国医学影像学杂志,2015,23(11):808-811.
[11]
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(4):378-390.
[12]
Cheng AL, Kang YK, Chen Z,et a1.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol,2009,10(1):25-34.
[13]
Lim S, Han J, Kim GM, et al. Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib[J]. J Gastroenterol Hepatol,2015,30(6):1024-1031.
[14]
Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial[J]. Int J Cancer,2015,136(6):1458-1467.
[15]
Welker MW, rojan J. Anti-angiogenesis in hepatoeellular carcinoma treatment:current evidence and future perspectives[J]. World J Gastroenterol,2011,17(26):3075-3081.
[16]
Pawlik TM, Reyes DK, Cosgrove D, et al. Phase Ⅱ trial of sorafenib combined with concurrent transarterial chemoembolization with drugeluting beads for hepatocellular carcinoma[J]. J Clin Oncol,2011,29(30):3960-3967.
[17]
常中飞,王茂强,刘凤永, 等. 综合治疗巨大肝癌的临床疗效及预后因素分析[J]. 中华肿瘤杂志,2014,36(1):59-62.
[18]
Adhoute X, Pénaranda G, Raoul JL, et al. Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study[J].Eur J Gastroenterol Hepatol,2016,28(4):433-440.
[19]
Wang K, Guo WX, Chen MS, et al. Multimodality treatment for hepatocellular carcinoma with portal vein tumor thrombus: a large-scale, multicenter, propensity mathching score analysis[J]. Medicine (Baltimore),2016,95(11):e3015.
[20]
Xiao CZ, Wei W, Guo ZX, et al. A prognosis model for patients with hepatocellular carcinoma and portal vein tumor thrombus following hepatic resection[J]. Oncol Lett,2015,10(5)2787-2794.
[21]
Yoon SM, Lim YS, Won HJ, et al. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes [J]. Int J Radiat Oncol Biol Phys,2012,82(5):2004-2011.
[22]
Solbiati L, Lerace T, Tonolini M, et al. Guidance and monitoring of radiofrequency liver tumor ablation with contrast-enhanced ultrasound[J]. Eur J Radiol,2004,51(Suppl):S19-S23.
[23]
陈敏山,李锦清,梁惠宏, 等. 经皮射频消融与手术切除治疗小肝癌的疗效比较[J]. 中华医学杂志,2005,85(2):80-83.
[24]
陈敏山. 肝癌射频消融治疗及综合治疗[J]. 中华医学杂志,2015,95(27):2174-2177.
[25]
Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial[J]. Radiology,2012,262(2):689-700.
[26]
Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization [J]. Cancer,2010,116(23):5452-5460.
[1] 汪洪斌, 张红霞, 何文, 杜丽娟, 程令刚, 张雨康, 张萌. 低级别阑尾黏液性肿瘤与阑尾黏液腺癌超声及超声造影特征分析[J/OL]. 中华医学超声杂志(电子版), 2024, 21(09): 865-871.
[2] 李子禹, 卢信星, 李双喜, 陕飞. 食管胃结合部腺癌腹腔镜手术重建方式的选择[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 5-8.
[3] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[4] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[5] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[6] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[7] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[8] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[9] 杨建波, 马欢, 黄小梅, 刘华柱. 结肠镜辅助下EMR、CSP和RFA术治疗直径<1cm结直肠息肉的疗效和安全性比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 76-79.
[10] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[11] 冯旺, 马振中, 汤林花. CT扫描三维重建在肝内胆管细胞癌腹腔镜肝切除术中的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 104-107.
[12] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[13] 燕速, 霍博文. 腹腔镜食管胃结合部腺癌根治性切除术[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 13-13.
[14] 郭兵, 王万里, 何凯, 黄汉生. 腹腔镜下肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 143-143.
[15] 魏丽霞, 张安澜, 周宝勇, 李明. 腹腔镜下Ⅲb型肝门部胆管癌根治术[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(01): 145-145.
阅读次数
全文


摘要